ReviewImmuno-oncology technology2023
Lymph node targeting for immunotherapy.
Review in Immuno-oncology technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026Review
- Defined distribution and features of lymph node therapies enable recruitment and manipulation of antigen-specific T cell response.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunity.bioRxiv : the preprint server for biology · 2026Article
- Engineering Anti-Tumor Immunity: An Immunological Framework for mRNA Cancer Vaccines.Vaccines · 2025Review
- Tumor-Draining Lymph Node-Targeted Electrochemotherapy: A Hypothesis for In Situ Cancer Vaccination.Biomedicines · 2025Review
- Super-adjuvant nanoparticles for platform cancer vaccination.Cell reports. Medicine · 2025Article
- Adoptively transferred macrophages for cancer immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) againstBioactive materials · 2025Article
- Viral Infection and Dissemination Through the Lymphatic System.Microorganisms · 2025Review
- Synthetic organic materials for targeting immunotherapies to lymph nodes.Chemistry of materials : a publication of the American Chemical Society · 2024Article
- Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis.Journal of nanobiotechnology · 2024Article
- Three-Dimensional Lymphatics-on-a-Chip Reveals Distinct, Size-Dependent Nanoparticle Transport Mechanisms in Lymphatic Drug Delivery.ACS biomaterials science & engineering · 2024Article
- Lymphatic system regulation of anti-cancer immunity and metastasis.Frontiers in immunology · 2024Review
- Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications.Biomaterials research · 2024Review
- Integrative multi-omics, network pharmacology, and molecular simulation of herbal compounds targeting immune tolerance mechanisms in food allergy.Journal of advanced pharmaceutical technology & researchArticle
- Abscopal Effect Induced by LAG-3/PD-1 Inhibition and Radiation Therapy in Metastatic Acral Melanoma: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immunotherapy that aims to boost the body's immune responses against pathogens or diseased cells has achieved significant progress for treating different diseases over the past several decades, especially with the success of checkpoint blockades, chimeric antigen receptor T therapy, and cancer vaccines in clinical cancer treatment. Effective immunotherapy necessitates the generation of potent and persistent humoral and T-cell responses, which lies in the ability of modulating and guiding antigen-presenting cells to prime antigen-specific T and B cells in the lymphoid tissues, notably in the lymph nodes proximal to the disease site. To this end, various types of strategies have been developed to facilitate the delivery of immunomodulatory agents to immune cells (e.g. dendritic cells and T cells) in the lymph nodes. Among them, intranodal injection enables the direct exposure of immunomodulators to immune cells in lymph nodes, but is limited by the technical challenge and intrinsic invasiveness. To address, multiple passive and active lymph node-targeting technologies have been developed. In this review, we will provide an overview of different lymph node-targeting technologies developed to date, as well as the mechanism and merits of each approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.